Cadzow Murray, Merriman Tony R, Dalbeth Nicola
Department of Biochemistry, University of Otago, Dunedin, New Zealand.
Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, New Zealand.
Arthritis Res Ther. 2017 Aug 9;19(1):181. doi: 10.1186/s13075-017-1390-1.
Many different combinations of available data have been used to identify gout cases in large genetic studies. The aim of this study was to determine the performance of case definitions of gout using the limited items available in multipurpose cohorts for population-based genetic studies.
This research was conducted using the UK Biobank Resource. Data, including genome-wide genotypes, were available for 105,421 European participants aged 40-69 years without kidney disease. Gout definitions and combinations of these definitions were identified from previous epidemiological studies. These definitions were tested for association with 30 urate-associated single-nucleotide polymorphisms (SNPs) by logistic regression, adjusted for age, sex, waist circumference, and ratio of waist circumference to height. Heritability estimates under an additive model were generated using GCTA version 1.26.0 and PLINK version 1.90b3.32 by partitioning the genome.
There were 2066 (1.96%) cases defined by self-report of gout, 1652 (1.57%) defined by urate-lowering therapy (ULT) use, 382 (0.36%) defined by hospital diagnosis, 1861 (1.76%) defined by hospital diagnosis or gout-specific medications and 2295 (2.18%) defined by self-report of gout or ULT use. Association with gout at experiment-wide significance (P < 0.0017) was observed for 13 SNPs with gout using the self-report of gout or ULT use definition, 12 SNPs using the self-report of gout definition, 11 SNPs using the hospital diagnosis or gout-specific medication definition, 10 SNPs using ULT use definition and 3 SNPs using hospital diagnosis definition. Heritability estimates ranged from 0.282 to 0.308 for all definitions except hospital diagnosis (0.236).
Of the limited items available in multipurpose cohorts, the case definition of self-report of gout or ULT use has high sensitivity and precision for detecting association in genetic epidemiological studies of gout.
在大型基因研究中,已使用多种不同的可用数据组合来识别痛风病例。本研究的目的是利用基于人群的基因研究的多用途队列中可用的有限项目,确定痛风病例定义的性能。
本研究使用了英国生物银行资源。共有105421名年龄在40 - 69岁且无肾脏疾病的欧洲参与者的数据,包括全基因组基因型。痛风定义及其组合是从先前的流行病学研究中确定的。通过逻辑回归对这些定义与30个尿酸盐相关单核苷酸多态性(SNP)进行关联测试,并对年龄、性别、腰围以及腰围与身高的比值进行调整。使用GCTA版本1.26.0和PLINK版本1.90b3.32通过划分基因组,在加性模型下生成遗传力估计值。
通过痛风自我报告定义的病例有2066例(1.96%),通过使用降尿酸治疗(ULT)定义的有1652例(1.57%),通过医院诊断定义的有382例(0.36%),通过医院诊断或痛风特异性药物定义的有1861例(1.76%),通过痛风自我报告或ULT使用定义的有2295例(2.18%)。使用痛风自我报告或ULT使用定义,观察到13个SNP与痛风在全实验显著性水平(P < 0.0017)上相关;使用痛风自我报告定义,有12个SNP相关;使用医院诊断或痛风特异性药物定义,有11个SNP相关;使用ULT使用定义,有10个SNP相关;使用医院诊断定义,有3个SNP相关。除医院诊断定义(0.236)外,所有定义的遗传力估计值范围为0.282至0.308。
在多用途队列中可用的有限项目中,痛风自我报告或ULT使用的病例定义在痛风遗传流行病学研究中检测关联具有高敏感性和精确性。